General Information
Merck Migraine 065
A Six Month Phase II/III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of Telcagepant (MK-0974) for Prevention of Menstrually Related Migraine in Female Patients with Episodic Migraine
| Protocol | MK-0974-065-00 |
|---|---|
| Identifier | MK-0974-065-00 |
| UID | 604c651c-8803-47a8-a14a-8cd56e8741df |
| Status | Done - Archived |
| Phase | 2/3 |
| Category | Migraine / Adult |
| Launch Year | 2010 |
| NCT Number | - |
| Created | 2010-06-18 14:24 |
| Last Updated | 2010-06-18 14:24 |
Description
No description provided.
Comment
No comment.
Target Dates
| Name | Date | Required |
|---|---|---|
| Enrollment Closed | 2010-09-30 | No |
| Enrollment Open | 2010-06-15 | No |
| First Patient First Visit | No | |
| Site Initiation Mtg. | 2010-01-01 | No |
| PI Meeting Start | No | |
| PI Meeting End | No | |
| PI Meeting Arrival | No | |
| PI Meeting Departure | No | |
| Closeout Date | 2011-05-11 | No |
| Final PatientVisit | No | |
| PreStudy Selection Visit | No | |
| Target Date 12 | No | |
| Target Date 13 | No | |
| Target Date 14 | No |
Leadership
| Role | Staff | Login | Required |
|---|---|---|---|
| Principal | Unger, Jeffrey | JUnger | No |
| Recruiter | - | No | |
| Coordinator | Mata, Nelly | NMata | No |
| Regulatory | Aguirre, Sandra | SAguirre | No |
Custom Fields
No custom fields.
Sponsor & Organization
| Sponsor | Merck Inc. |
|---|---|
| Division | Merck Inc. |
| Team | Merck Inc. |
| Managing Site | Catalina Research Institute, LLC |
| Organization |
Contacts
| IRB Ref | |
|---|---|
| CRO | |
| CRO Ref | |
| Correspondence | 0 |
Opportunity
| Probability | 0 |
|---|---|
| Comment | |
| Status Color | Gainsboro |
| Currency | - |
